ZyversaREV_cmyk.jpg
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
14 mai 2024 07h57 HE | ZyVersa Therapeutics
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.
Elevar Logo for Common Use.png
Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization
01 juin 2023 08h00 HE | Elevar Therapeutics
FORT LEE, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Picture1.jpg
Oncotelic Participating at 2023 BIO International Convention
16 mai 2023 08h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases...
Picture1.jpg
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
15 juin 2022 07h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
image
Qualigen Therapeutics to Present at BIO International Convention
14 juin 2022 09h00 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Picture1.jpg
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention
18 mai 2022 08h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Syneos Health_rgb_tm.png
Syneos Health Consulting Releases 11th Annual Survey of Biopharmaceutical Dealmakers
05 juin 2019 12h15 HE | Syneos Health, Inc.
PHILADELPHIA, June 05, 2019 (GLOBE NEWSWIRE) -- The 11th annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading biopharmaceutical management consulting firm,...
Syneos Health_rgb_tm.png
Syneos Health to Present Actionable Commercial Insights Designed for Biopharmaceutical Companies at BIO International Convention
05 juin 2018 08h55 HE | Syneos Health
RALEIGH, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and...
Top European Biotech, Pharma Executives Gathering to Discuss San Diego Strategic Business Partnerships
16 juin 2014 16h53 HE | European American Enterprise Council
SAN DIEGO, CA--(Marketwired - Jun 16, 2014) - Senior executives from leading European biotech and pharma companies will discuss how public and private sector organizations in San Diego can best...
Avid Bioservices to Present a Case Study on cGMP Production Scale-Up, Optimization and Transition From a Stainless Steel to a Fully Disposable Process at BIO International Convention
19 avr. 2013 13h00 HE | Avid Bioservices
TUSTIN, CA--(Marketwired - Apr 19, 2013) - Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals, Inc., today announced its upcoming participation at the Biotechnology Industry...